Drug Profile


Alternative Names: WST-1; WST01; WST1/analgesic

Latest Information Update: 10 Aug 2016

Price : $50

At a glance

  • Originator University of Manitoba
  • Developer WinSanTor
  • Class
  • Mechanism of Action Sensory receptor cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Neuropathic pain
  • Preclinical Diabetic neuropathies

Most Recent Events

  • 10 Aug 2016 Phase-I clinical trials in Neuropathic pain in Australia (Topical)
  • 10 Aug 2016 Preclinical trials in Diabetic neuropathies in USA (Topical)
  • 10 Aug 2016 Early research in Neuropathic pain in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top